Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.57 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | DRD1 | P21728 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 2/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20150695 | 0.87 | CYP3A4 (0.43) | CYP3A4DRD4DRD2DRD3SLC18A2 | |
| SCHEMBL20150693 | 0.86 | CYP3A4 (0.46) | CYP3A4SLC6A2SLC6A4SLC6A3DRD1 | |
| SCHEMBL20150779 | 0.76 | CYP3A4 (0.47) | CYP3A4SLC6A2SLC6A4SLC6A3DRD1 | |
| Dihydrokawain SCHEMBL18214381 | 0.72 | CYP3A4 (1.00) | CYP3A4SLC6A2SLC6A4SLC6A3DRD4 | |
| Dihydrokawain SCHEMBL2743647 | 0.72 | CYP3A4 (1.00) | CYP3A4SLC6A2SLC6A4SLC6A3DRD4 | |
| Dihydrokawain SCHEMBL5672433 | 0.72 | CYP3A4 (1.00) | CYP3A4SLC6A2SLC6A4SLC6A3DRD4 | |
| SCHEMBL22335739 | 0.72 | TSHR (0.40) | NPC1RAB9A | |
| SCHEMBL20150714 | 0.71 | CYP3A4 (0.39) | CYP3A4SLC6A2SLC6A4SLC6A3CYP2C19 | |
| SCHEMBL24137898 | 0.66 | MEN1 (0.62) | CYP3A4SLC6A2SLC6A4SLC6A3DRD4 | |
| SCHEMBL2077308 | 0.66 | MEN1 (0.62) | CYP3A4SLC6A2SLC6A4SLC6A3DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10624943-B2 | Kava derived therapeutic compounds and methods of use thereof | Kuality Herbceutics, LLC (US) | 2020-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10624943-B2 | Kava derived therapeutic compounds and methods of use thereof | KLK5, KLK4, KLK2 | CYP3A4 745/4885SLC6A2 2985/4885SLC6A4 3243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.